Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 2Terminated 1Recruiting 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 2Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Large B-Cell, Diffuse 1

Interventions

Rituximab 39Cyclophosphamide 35Magnetic Resonance Spectroscopy 22Specimen Handling 20Doxorubicin 18polatuzumab vedotin 17Prednisone 17Lenalidomide 15Biopsy 15fludarabine 13Oxaliplatin 13Gemcitabine 13zanubrutinib 11Vincristine 11Immunotherapy, Adoptive 10Etoposide 10glofitamab 9axicabtagene ciloleucel 7Prednisolone 7obinutuzumab 6N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 6Leukapheresis 6Injections 6Ifosfamide 6Bendamustine Hydrochloride 6loncastuximab tesirine 5ibrutinib 5acalabrutinib 5Carboplatin 5CT-P10 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Lymphoma, Large B-Cell, Diffuse × EPOCH protocol × Clear all
NCT04002947 2026-06-03

Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
132 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡